Torsdag 27 November | 19:24:55 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-06-04 07:00 Bokslutskommuniké 2026
2026-03-02 07:00 Kvartalsrapport 2026-Q3
2025-11-21 - Kvartalsrapport 2026-Q2
2025-11-10 - Extra Bolagsstämma 2025
2025-10-29 - Årsstämma
2025-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2025-09-01 - Kvartalsrapport 2026-Q1
2025-06-03 - Bokslutskommuniké 2025
2025-03-03 - Kvartalsrapport 2025-Q3
2024-12-04 - Kvartalsrapport 2025-Q2
2024-09-26 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2023-12-04 - Kvartalsrapport 2024-Q2
2023-10-04 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 - Årsstämma
2023-08-31 - Kvartalsrapport 2024-Q1
2023-06-08 - Bokslutskommuniké 2023
2023-03-01 - Kvartalsrapport 2023-Q3
2022-12-01 - Kvartalsrapport 2023-Q2
2022-10-03 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-10 - Bokslutskommuniké 2022
2022-03-02 - Kvartalsrapport 2022-Q3
2021-12-02 - Kvartalsrapport 2022-Q2
2021-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 - Kvartalsrapport 2022-Q1
2021-05-31 - Bokslutskommuniké 2021
2021-03-03 - Kvartalsrapport 2021-Q3
2020-12-02 - Kvartalsrapport 2021-Q2
2020-09-30 - Årsstämma
2020-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 - Kvartalsrapport 2021-Q1
2020-06-08 - Bokslutskommuniké 2020
2020-04-20 - Extra Bolagsstämma 2020
2020-03-02 - Kvartalsrapport 2020-Q3
2019-12-02 - Kvartalsrapport 2020-Q2
2019-09-30 - Årsstämma
2019-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 - Kvartalsrapport 2020-Q1
2019-06-10 - Bokslutskommuniké 2019
2019-03-04 - Kvartalsrapport 2019-Q3
2018-12-17 - Kvartalsrapport 2019-Q2
2018-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 - Årsstämma
2018-09-24 - Kvartalsrapport 2019-Q1
2018-06-25 - Bokslutskommuniké 2018
2018-03-26 - Kvartalsrapport 2018-Q3
2017-12-18 - Kvartalsrapport 2018-Q2
2017-09-25 - Årsstämma
2017-09-25 - Kvartalsrapport 2018-Q1
2017-06-30 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Bolaget utvecklar system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-18 16:12:13

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES.

November 17, 2025, was the first day of the subscription period in Integrum AB's ("Integrum" or the "Company") rights issue of shares of series B that was resolved by the Board of Directors on October 16, 2025, and approved by the extraordinary general meeting on November 10, 2025 (the "Rights Issue"). The subscription period runs until December 1, 2025. However, please note that some banks and nominees may have an earlier response deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an earlier response date for the subscription.

Summary of the Rights Issue

  • The net proceeds from the Rights Issue will be used for business development and marketing, personnel and operations, R&D and product development, regulatory and clinical investments, operational efficiency and supply chain flexibility, and to ensure financial stability.
  • The Rights Issue comprises up to 5,333,582 shares of series B with a subscription price of SEK 8.0 per share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 42.6 million before deduction of costs related to the Rights Issue.
  • Each share, regardless of series, in the Company held on the record date November 13, 2025 entitled the holder to one (1) subscription right. Four (4) subscription rights entitle the holder to subscribe for one (1) new share of series B.
  • The last day of trading in the Company's shares including the right to participate in the Rights Issue is November 11, 2025.
  • The subscription period will run from and including November 17, 2025, to and including December 1, 2025.
  • Trading in subscription rights will take place on Nasdaq First North Growth Market during the period from and including November 17, 2025, to and including November 26, 2025, and trading in paid subscribed shares (BTA) will occur during the period from and including November 17, 2025, to and including December 10, 2025.
  • The Rights Issue is covered by subscription commitments and guarantee commitments corresponding to 100 percent of the issue amount. However, the subscription commitments and the guarantee commitments are not secured by bank guarantees, escrow accounts, pledges or similar arrangements.
  • No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document (the "Information Document") in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation").
  • Complete terms and conditions and instructions for the Rights Issue, as well as other information, are set out in the Information Document which has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the Company's website www.integrum.se.

Timetable for the Rights Issue

17 November - 26 November 2025 Trading in subscription rights.
17 November - 1 December 2025 Subscription period.
17 November - 10 December 2025 Trading in paid subscribed shares (BTA).
2 December 2025 Expected announcement of the outcome of the Rights Issue.

Advisors

Integrum has engaged DNB Carnegie Investment Bank AB (publ), and Setterwalls Advokatbyrå AB as financial and legal advisers in connection with the Rights Issue.